SOLAI Limited vs Tilray Brands Inc — how do they compare? SOLAI Limited trades at $3.72 (market cap $16.69M), while Tilray Brands Inc trades at $4.21 (market cap $577.15M). The key difference: Tilray Brands Inc is far larger — about 34.6× SOLAI Limited's market cap. Which is the better fit depends on your goals.
| SLAI | TLRY | |
|---|---|---|
Market Cap | $16.69M | $577.15M |
Sector | Technology | Health |
52-Week High | $21.63 | $21.00 |
52-Week Low | $2.74 | $3.88 |
Enterprise Value | $16.33M | $744.29M |
Signals from Pluang's Aura AI — not financial advice
SLAI trades at $3.72 with no recent price movement, showing technical bullish signals despite fundamental challenges. The company reported negative financial metrics including -$33.88M net income and -134.63% net margin for 2025, though it beat Q2 2025 EPS expectations. Recent corporate actions include a 7:1 reverse stock split effective July 2026 and a NYSE delisting notice, creating significant uncertainty for investors.
The outlook remains highly speculative with substantial operational risks offset by low valuation multiples. Investment opportunity exists only for risk-tolerant investors betting on the AI infrastructure turnaround, while delisting proceedings and persistent losses present severe downside risks requiring careful monitoring of corporate developments.
TLRY trades at $4.30, down 4.44% with a bearish technical outlook. The company reported record fiscal 2026 revenue of $915M but continues to post significant losses with a -13.27% net margin. Recent news highlights expansion in spirits distribution and medical cannabis production, though regulatory uncertainty weighs on sentiment. The stock trades below book value with a P/S of 0.51 and P/B of 0.36, suggesting potential undervaluation despite profitability challenges.
TLRY presents a high-risk opportunity with mixed signals. The discounted valuation and expanding beverage/alcohol business offer upside potential, but persistent losses, negative cash flow, and cannabis regulatory delays create substantial headwinds. Analyst consensus leans cautious with 65% hold ratings, reflecting the stock's speculative nature amid ongoing operational challenges.
Trailing returns across standard periods
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →